Tolterodine Indications
Tolterodine is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency 1.
Primary Indication
The FDA-approved indication is straightforward and encompasses the core symptom complex of OAB 1:
- Urge urinary incontinence (involuntary urine loss associated with urgency)
- Urgency (sudden compelling desire to void that is difficult to defer)
- Frequency (increased number of micturitions per 24 hours)
Patient Populations
Women with OAB
Tolterodine extended-release has demonstrated efficacy and tolerability in both male and female patients with overactive bladder 2. The 2019 AUA/SUFU guidelines reference combination therapy studies that included predominantly female populations (80% women), supporting its use across genders 3.
Men with OAB and Lower Urinary Tract Symptoms
Tolterodine is safe and effective in men with OAB symptoms, including those with presumed non-obstructive benign prostatic hyperplasia 2. Multiple studies from the 2023 EAU guidelines demonstrate:
- Safety and efficacy in men with OAB symptoms and presumed non-obstructive BPH 2
- Efficacy in men with urgency urinary incontinence 2
- Tolerability even in men with bladder outlet obstruction, with no clinically meaningful increase in urinary retention risk 2
The landmark JAMA trial showed that combination tolterodine ER plus tamsulosin provided superior benefit in men with moderate to severe LUTS including OAB, with low incidence of acute urinary retention (0.4%) 4.
Special Populations
Menopausal women: The 2019 AUA/SUFU guidelines cite evidence for tolterodine use in combination with intravaginal estradiol cream in menopausal women with OAB 3.
Patients with nocturia: Tolterodine can be dosed at nighttime (≤4 hours before bed) to specifically target OAB-related nocturnal micturitions, though it does not affect normal (non-OAB) micturitions 5. In combination with desmopressin, it may benefit patients with nocturnal polyuria 3.
Important Clinical Context
What Tolterodine Does NOT Treat
Tolterodine is contraindicated in patients with 1:
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Hypersensitivity to tolterodine or fesoterodine
Mechanism-Based Expectations
As an antimuscarinic agent, dry mouth is the most common adverse effect (occurring in 35% vs 10% placebo), though it is predominantly mild-to-moderate 1. The drug shows functional selectivity for bladder over salivary glands, resulting in better tolerability compared to older antimuscarinics like oxybutynin 6, 7.
Practical Prescribing Algorithm
Confirm OAB diagnosis: Symptoms of urgency ± urge incontinence, frequency (≥8 micturitions/24h), with or without nocturia, in absence of infection or pathology
Exclude contraindications: Check for urinary retention, gastric retention, uncontrolled narrow-angle glaucoma
Consider patient factors:
Dosing: Tolterodine ER 4 mg once daily or immediate-release 2 mg twice daily; nighttime dosing option available for nocturia-predominant symptoms